Defunct Company
Total Trials
29
As Lead Sponsor
5
As Collaborator
24
Total Enrollment
4,169
NCT00336505
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)
Phase: Phase 3
Role: Lead Sponsor
Start: Dec 31, 2005
Completion: Oct 31, 2007
NCT00336544
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia
Start: Jun 30, 2006
Completion: May 31, 2007
NCT00701987
Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma
Phase: Phase 1
Start: Jun 30, 2008
Completion: Not specified
NCT00867906
Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma
Phase: Phase 2
Role: Collaborator
Start: Mar 31, 2009
Completion: Apr 30, 2010
NCT00878774
Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis
Start: Apr 30, 2009
Completion: Nov 30, 2009
NCT01008332
Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis
Start: Nov 30, 2009
Completion: Aug 31, 2010
NCT01033344
Cat-PAD Exposure Chamber Study
Start: Jan 31, 2010
Completion: Sep 30, 2010
NCT01166061
Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis
Start: Jul 31, 2010
Completion: Apr 30, 2011
NCT01198613
ToleroMune Ragweed Exposure Chamber Study
Start: Sep 30, 2010
Completion: Aug 31, 2011
NCT01272323
Cat-PAD Follow on Study
Phase: N/A
Start: Feb 28, 2011
NCT01361412
Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy
Start: Mar 31, 2011
Completion: Sep 30, 2011
NCT01385800
ToleroMune Grass Exposure Unit Study
Start: Aug 31, 2011
Completion: Aug 31, 2013
NCT01447784
ToleroMune House Dust Mites (HDM) Exposure Chamber Study
Start: Sep 30, 2011
Completion: May 31, 2013
NCT01383590
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis
Start: Oct 31, 2011
Completion: Dec 31, 2013
NCT01383603
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
Completion: May 31, 2014
NCT01448603
ToleroMune Ragweed Follow up Study
Completion: Mar 31, 2012
NCT01604018
An Optional Two Year Follow Up Study to Study CP005A
Start: Feb 29, 2012
Completion: Apr 30, 2012
NCT01923779
ToleroMune Grass Follow on Study
Start: May 31, 2013
Completion: Sep 30, 2013
NCT01923792
ToleroMune House Dust Mite Follow on Study
Start: Sep 30, 2013
Completion: Apr 30, 2014
NCT01949415
An Optional Investigation of Biomarkers of Efficacy
NCT01949441
ToleroMune House Dust Mite (HDM) Tolerability Study
NCT02061670
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma
Start: Jan 31, 2014
Completion: Oct 31, 2014
NCT02061709
Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber
NCT02161107
Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma
Start: Apr 30, 2014
Completion: Mar 31, 2015
NCT02292875
Completion: Sep 30, 2014
NCT02396680
Ragweed-SPIRE Follow-On Study
Start: Apr 30, 2015
NCT02478060
Birch-SPIRE Safety and Efficacy Study
Start: Jul 31, 2015
NCT02601690
Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
Start: Oct 31, 2015
Completion: Jun 25, 2017
NCT04969835
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Start: Jul 16, 2021
Completion: Aug 15, 2026